Addex Therapeutics announced robust anti-tussive activity of its GABAB PAM candidate in a non-human primate chronic cough model, comparable to baclofen with potentially better tolerability.
Key takeaways
GABAB PAM candidate significantly reduced citric acid-induced cough frequency in NHP chronic cough model.
Anti-tussive efficacy similar to baclofen in NHP model.
Previously showed superior efficacy to nalbuphine, baclofen, codeine, P2X3 inhibitor in guinea pig model.
Demonstrated better tolerability and wider therapeutic margin than nalbuphine, baclofen, codeine.
CEO states potential as once-daily treatment for chronic cough without baclofen's side effects.